OUR
PRACTICE
AZB advises companies engaged in a range of activities in the pharmaceuticals sector, from the manufacture of products, Active Pharmaceutical Ingredients, injectables, infusions, etc., to wholesale distribution and navigating the online marketplace to distribute these products. The team has, over the years and through multiple deals, gained specialised sectoral knowledge of the commercial and legal aspects, such as loan licensing, marketing authorisations, good manufacturing practices, and so on, which brings true value addition to business strategies and transactions.
GET IN TOUCH
-
Darshika Kothari
Senior Partner
-
Vinati Kastia
Senior Partner
-
Srinath Dasari
Senior Partner
-
Nandan Pendsey
Partner
Houses a notable team offering significant expertise in IP matters, assisting a range of multinational corporates in the life sciences sector. Handles the full range of work, from brand portfolio management and patent prosecution to IP-related contentious work. Regularly advises major pharmaceutical companies on regulatory issues. Works closely with the firm's corporate team to handle investments into the life sciences sector.
Chambers & Partners Asia–Pacific (2022) on our Life Sciences TeamWHAT
WE DO
Irrespective of the level of complexity, our domain expertise promises a focused efficiency and prompt, result–oriented solutions. We regularly assist our clients with fund raising from various global funds and private equity investors on their acquisitions, both offshore and onshore. On the litigation side, we represent companies in disputes with regulatory authorities and third parties.
Our full–service offering brings the additional advantage of cross–domain competencies; the Intellectual Property practice engages with clients on registration and trademarks, patents and marketing authorisations, as well as compliance with data privacy laws. This further extends to strategic investments and mergers and acquisitions.
RECENT WORK HIGHLIGHTS
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
-
On the laws (i) Governing its interactions with India medical practitioners (ii) Pertaining to stent pricing and recall in India
-
On (i) Its acquisition of the Active Pharmaceutical Ingredient manufacturing division of Sanmar Speciality Chemicals (ii) The sale of its API facility Nuray Chemicals
-
On its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with a presence in India and emerging markets
-
On (i) Developing and commercialising production of its active pharma ingredients (ii) Managing its IP (iii) Complying with Indian regulatory requirements
-
On Evermed Holdings’ subscription of approximately 55% of it share capital for USD 60 million
-
On the laws and regulations governing interactions with medical practitioners in India
-
On (i) On developing and securing its IP rights (ii) Its agreements on a research partnership with Syngene, a wholly owned subsidiary of Biocon
-
On its majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, for USD 210 million, followed by a mandatory open offer under the SEBI takeover regulations
-
On its minority acquisition of Narayana Hruduyalaya, for USD 50 million
-
On the transfer of its infusion business for India and emerging markets on its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for USD 170 million
-
On its (i) Invoicing issues in India, in view of the new GST regime (ii) Its distribution related arrangements (iii) Data privacy issues relating to its third party payroll services agreement
-
On (i) Laws governing the import of medical devices into India (ii) Interactions with medical practitioners
-
On (i) Its acquisition of a stake in several companies, such as Balsara Group and Fem Care Pharma (ii) IFC’s PE investment in Dabur Pharma (iii) The sale of its non-oncology formulations business to Alembic
-
On (i) Its acquisition and subsequent sale of Nephrolife Care (India) (ii) Its 49% acquisition of Express Clinics
-
On the (i) Demerger of its female contraceptive business into Jai Pharma Ltd (ii) USD 800 million sale of JPL by FPL’s existing shareholders to Mylan Laboratories
-
On the Indian regulations governing Genetically Modified Organisms and associated product liability risks
-
On its minority share acquisition in GlaxoSmithkline Consumer Healthcare for USD 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations
-
On the sale of its pharma contract development and manufacturing business in India, the US and Sweden, to Recipharm AB
-
On General Atlantic’s USD 130 million equity investment in KIMS
-
On its (i) 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute (ii) Majority acquisition of Max India’s allied health business (iii) Minority acquisition of Max Ventures Investment Holdings
-
On its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products
-
On (i) Warburg Pincus’ PE investment in Max India and Max Healthcare (ii) Its JV with Nova Medical Centres for day care surgical centres (iii) Its 54% acquisition of Saket City Hospitals from Smart Health City
-
On (i) Laws governing foreign physicians to collaborate and provide medical advice to patients based in India (ii) Compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions
-
On (i) Licensing requirements and transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017 (ii) Issues relating to the price control of ‘coronary stents’
-
On (i) Licensing and supplying its pharmaceutical products and vaccines (ii) Managing its IP (iii) Complying with regulatory requirements in India
-
On (i) License agreements for its gene sequencing technology (ii) Laws relating to Good Clinical Practice Guidelines, clinical trials, interaction with investigators, biomedical research and export/shipment of biological samples outside India
-
On laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting
-
On (i) Implications of a common law license (ii) Laws and regulations governing the online sale of drugs in India and interactions with medical practitioners
-
On (i) The sale of its Capsugel business to KKR (ii) The global restructuring of its animal health business, including the divestment of its Indian animal health business (iii) Laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials
-
On the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor
-
On successfully enforcing its brand ‘Chymoral Forte’ against Wockhardt
-
Its acquisition of (i) A minority stake in Manipal Health Enterprises, Manipal Group’s healthcare arm, for USD 145.75 million (ii) A majority stake in Cancer Treatment Services
-
On the laws and regulations governing the advertising and marketing of medical devices in India
